US20090264390A1 - Topical Personal Care Compositions And Methods of Use - Google Patents

Topical Personal Care Compositions And Methods of Use Download PDF

Info

Publication number
US20090264390A1
US20090264390A1 US12/492,681 US49268109A US2009264390A1 US 20090264390 A1 US20090264390 A1 US 20090264390A1 US 49268109 A US49268109 A US 49268109A US 2009264390 A1 US2009264390 A1 US 2009264390A1
Authority
US
United States
Prior art keywords
composition
hair
hydrocortisone
phytantriol
panthenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/492,681
Inventor
Asher Wagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pure USA LLC
Original Assignee
Pure USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pure USA LLC filed Critical Pure USA LLC
Priority to US12/492,681 priority Critical patent/US20090264390A1/en
Assigned to Pure USA, LLC reassignment Pure USA, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WAGH, ASHER
Publication of US20090264390A1 publication Critical patent/US20090264390A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair

Definitions

  • Topical personal care compositions containing the anti-inflammatory agent cortisone are well known in the art.
  • Adrenal corticosteroids, and the synthetic analogues thereof are active pharmaceutical compounds with the known characteristic of preventing the development of, or suppressing existing, localized heat, redness, tenderness and swelling which characterizes any inflammation of skin or mucous membrane, regardless of the causal factor.
  • the unique biochemical, pharmacologic and physiologic properties of corticosteroids make them extremely useful in the topical treatment of inflammatory conditions in subjects.
  • anti-inflammatory agents are effective in the treatment of various skin and scalp disorders such as psoriasis, seborrhea, dermatitis, dandruff, and the like.
  • these compounds generally have been available in non-rinse vehicles which contain oils or emulsions which give the hair or skin a soiled appearance.
  • Surfactants may be added to an anti-inflammatory agent containing formulations to improve the appearance of hair and scalp.
  • U.S. Pat. No. 4,835,148 describes a shampoo composition comprising a water insoluble anti-inflammatory agent and an anionic surfactant.
  • U.S. Pat. No. 5,665,364 describes a topical personal care composition comprising both an anionic surfactant and an amphoteric surfactant, and an active ingredient, one of which may be hydrocortisone. While the addition of an anionic surfactant has been shown to decrease the oily appearance of the hair, it is not considered to be a gentle cleanser and can overstrip the hair and dry the scalp.
  • One or more embodiments of the present invention relate to topical personal care compositions comprising an effective amount of an anti-inflammatory agent, an effective amount of an surfactant, an effective amount of a bodifier/humectant, and water.
  • Certain embodiments of the present invention pertain to providing a gentle cleanser with a decreased likelihood of irritancy, while still allowing for a level of lather production that is acceptable to the consumer. While embodiments of the invention should not be limited by a particular principle, it is believed that these characteristics may be achieved in the current composition through the use of a surfactant as the cleansing agent. Certain embodiments of the present invention provide topical personal care compositions which contain a mild cleanser and do not overstrip the hair and/or dry the skin.
  • Embodiments of the present invention also relate to increasing the diameter of the hair shaft as well as moderating damage to the hair caused by environmental or other factors. This result may be effectuated though the use of a bodifier/humectant that is sorbable onto or into the shafts of the hair and is able to remain with the hair for a reasonable period of time. Additionally, the bodifier/humectant is believed to decrease the friction between individual shafts of hair, thereby decreasing abrasion damage caused by brushing or combing.
  • This embodiment of the present invention provides topical personal care compositions containing a cosmetically effective amount of a bodifier/humectant that can both increase the diameter of the hair shafts and moderate damage to the hair.
  • topical personal care compositions which are applied to hair and/or skin.
  • the topical personal care composition is worked through wet hair, and later rinsed off to provide the consumer with a scalp treatment in a mild cleansing composition that is gentle on the hair and scalp.
  • the topical personal care compositions are selected from the group consisting essentially of a body wash, cream, lotion, spray or shampoo.
  • the topical personal care composition comprises about 0.1% to about 5.0% of an anti-inflammatory agent; about 15.0% to about 55.0% of an amphoteric surfactant; about 0.1% to about 9.0% of bodifier/humectant; and water.
  • the anti-inflammatory agent in the above composition includes hydrocortisone.
  • the amphoteric surfactant in the above composition includes cocamidopropyl hydroxysultaine.
  • the bodifier/humectant includes panthenol, panthenyl ethyl ether, or phytantriol, or mixtures thereof.
  • the anti-inflammatory agent includes hydrocortisone
  • the amphoteric surfactant includes cocamidopropyl hydroxysultaine
  • the bodifier/humectant includes a mixture of panthenol, panthenyl ethyl ether, and phytantriol.
  • the composition comprises: about 0.1% to about 5.0% hydrocortisone; about 15.0% to about 55.0% cocamidopropyl hydroxysultaine; about 0.1% to about 9.0% panthenol, about 0.1% to about 9.0% panthenyl ethyl ether, and about 0.1% to about 9.0% phytantriol; and about 25.0% to about 70.0% water.
  • the composition is composed of: about 0.9% to about 1.1% hydrocortisone; about 30% to about 40% cocamidopropyl hydroxysultaine; about 1.0% to about 5.0% panthenol, about 0.5% to about 0.9% panthenyl ethyl ether, and about 0.1% to about 0.5% phytantriol; and about 25.0% to about 70.0% water.
  • Another aspect of the invention concerns a method of shampooing hair wherein an effective amount of an anti-inflammatory agent is deposited on the scalp comprising the steps of: (a) applying an effective amount of the topical personal care composition to hair that has been wetted; (b) working said composition through said hair; and (c) rinsing said composition from said hair.
  • the compositions comprise at least about 0.1% to about 6.0% of an anti-inflammatory agent.
  • the amount is from about 0.5% to about 4.0%, more preferably from about 0.9% to about 3.1%.
  • anti-inflammatory agent Any type of known anti-inflammatory agent may be useful in compositions of the present invention.
  • One preferred category of anti-inflammatory agents is the adrenal corticosteroids.
  • a preferred anti-inflammatory agent is hydrocortisone, a known anti-inflammatory agent which exists and is commercially available.
  • Another preferred anti-inflammatory agent is salicylic acid, a known anti-inflammatory agent which exists and is commercially available.
  • One component of the present compositions is a surfactant, which is for the delivery of conditioning agents to the hair and skin.
  • the A preferred amphoteric surfactant is and amphoteric surfactant.
  • a preferred amphoteric surfactant is cocamidopropyl hydroxysultaine.
  • Amphoterics also known as surface-active agents
  • the compositions comprise at least about 15.0% to about 55.0% of an amphoteric surfactant. Preferably the amount is from about 30.0% to about 40.0%.
  • amphoteric surfactants which can be used in the compositions of embodiments of the present invention are those broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • an anionic water solubilizing group e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • Examples of compounds falling within this definition are sodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminopropane sulfonate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isothionate according to the teaching of U.S. Pat. No. 2,658,072, N-higher alkyl aspartic acid esters such as those produced according to the teaching of U.S. Pat. No. 2,438,091, and the products sold under the trade name “Miranol” and described in U.S. Pat. No. 2,528,378.
  • Certain embodiments of the invention incorporate a bodifier/humectant that increases the diameter of the hair shafts and moderates the damage that environmental or other factors may have caused to hair or skin.
  • the bodifier remains with the hair and skin for a reasonable length of time to minimize future damage.
  • One preferred bodifier is comprised of panthenol, panthenyl ethyl ether, phytantriol, or mixtures thereof, and will comprise an effective amount of a bodifier/humectant, generally about 0.1% to about 9.0% by weight of the composition.
  • the bodifier/humectant according to certain embodiments of the present invention is also effective in moisturizing the skin.
  • the compositions comprise at least about 0.1% to about 9.0% of a bodifier/humectant. Preferably the amount is from about 0.1% to about 5.0%.
  • compositions contain from about 25.0% to about 70.0% water, preferably from about 34.0% to about 62.0%
  • compositions may include, but are not limited to: preservatives, such as sodium benzoate, methylchloroisothiazolinone, and methylisothiazolinone; anti-fungal agents, such as methylparaben and propylparaben; PEG-6000 distearate; lauramide DEA and linoleamide DEA; glycol stearate; and fragrance.
  • preservatives such as sodium benzoate, methylchloroisothiazolinone, and methylisothiazolinone
  • anti-fungal agents such as methylparaben and propylparaben
  • PEG-6000 distearate such as lauramide DEA and linoleamide DEA
  • glycol stearate such as glycol stearate
  • fragrance such as sodium benzoate, methylchloroisothiazolinone, and methylisothiazolinone
  • fragrance such as sodium benzoate, methylchloroisothiazol
  • anti-dandruff agents are also present in the shampoo compositions. Included among such agents are coal tar, sulfur, selenium sulfide, salicyclic acid, pyridinethione metal salts (e.g., zinc), ether 1-hydroxy pyridones such as those described in U.S. Pat. No. 4,185,106, and azole antimycotics disclosed in British Pat. No. 1,502,144, both of which patents are incorporated herein by reference in their entirety. When present, this additional anti-dandruff agent comprises from about 0.1% to about 7.0% of the composition, preferably from about 0.2% to about 2.0%.
  • the topical personal care compositions according to certain embodiments of the present invention may also comprise a suspending agent.
  • the suspending agent useful can be one of several agents, such as for example, ethylene glycol esters of fatty acids containing from about 16 to about 22 carbon atoms, preferably from about 16 to about 18 carbon atoms.
  • ethylene glycol esters which may include diesters wherein the esters are a mixture of palmitate and stearate.
  • the amount of stearate should be in the range of about 5.0% to about 20.0% or in the range of about 95.0% to about 80.0% with palmitate accounting for the remainder.
  • the amount of stearate is preferably from about 5.1% to about 10.5%.
  • the distearates found to be useful in certain embodiments of the compositions of the present invention range from about 5.0% to about 10.0%.
  • alkanol amides of fatty acids containing from about 16 to about 22 carbon atoms, preferably from about 16 to about 18 carbon atoms may be useful.
  • Preferred alkanol amides are stearic monoethanolamide stearic diethanolamide, stearic monoisopropanolamide and stearic monoethanolamide stearate.
  • Another useful group of suspending agents are alkyl dimethylamine oxides, wherein the alkyl group contains from about 16 to about 22 carbon atoms such as stearyldimethyl amine oxide.
  • compositions according to certain embodiments of the invention comprise from about 2.0% to about 11.0% of the suspending agent, preferably from about 5.0% to about 7.0%.
  • the topical personal care compositions according to one or more embodiments of the present invention can contain a variety of other nonessential optional components suitable for rendering such compositions more acceptable.
  • Such conventional optional ingredients are well known to those skilled in the art, e.g., preservatives such as benzyl alcohol, methyl paraben, propyl paraben, methylisothiazolinone and imidazolidinyl urea; thickeners and viscosity modifiers such as amine oxides, block polymers of ethylene oxide and propylene oxide such as Pluronic F88 offered by BASF Wyandotte, fatty alcohols such as cetearyl alcohol, sodium chloride, ammonium chloride, sodium sulfate, polyvinyl alcohol, propylene glycol and ethyl alcohol; hydrotopes such as xylene sulfonate, amine sulfonate, and polyethylene glycol; pH adjusting agents such as citric acid, succinic acid, phosphoric acid, sodium hydrox
  • compositions are free of clays and polymeric thickeners.
  • free refers to less than about 20 ppm.
  • composition is representative of the present invention.
  • composition is also representative of the present invention and is prepared as follows:
  • Example II The composition of Example II is prepared according to the following procedure:
  • step 1 of this method of manufacture water is heated to 75° C. and panthenol, lauramide DEA, panthenyl ethyl ether, phytantriol, and methylchloroisothiazolinone are added.
  • the reaction components of step 1 are mixed and the temperature is maintained at 75° C.
  • step 2 of the method of manufacture according to this embodiment of the invention, components cocamidopropyl hydroxysultaine, PEG-6000 distearate, glycol stearate, methylparaben, and propylparaben are mixed and heated to 75° C. until the components are dissolved.
  • the resultant reaction mixture of step 2 is then added to the final mixture of step 1.
  • the composition is continually mixed while cooling to 40° C.
  • step 3 of the method of manufacture according to this embodiment of the invention hydrocortisone and water are premixed and added to the resultant composition of step 2.
  • step 4 of the method of manufacture according to this embodiment of the invention components water and sodium benzoate are premixed and added to the resultant composition of step 3.
  • step 5 of the method of manufacture according to this embodiment of the invention lauramide DEA (and) linoleamide DEA, and fragrance are added to the resultant composition of step 4.
  • composition is also representative of the present invention.
  • composition is also representative of the present invention and is prepared as follows:
  • Example IV The composition of Example IV is prepared according to the following procedure:
  • step 1 of this method of manufacture water is heated to 75° C. and panthenol, lauramide DEA, panthenyl ethyl ether, phytantriol, and methylchloroisothiazolinone are added.
  • the reaction components of step 1 are mixed and the temperature is maintained at 75° C.
  • step 2 of the method of manufacture according to this embodiment of the invention, components cocamidopropyl hydroxysultaine, PEG-6000 distearate, glycol stearate, methylparaben, and propylparaben are mixed and heated to 75° C. until the components are dissolved.
  • the resultant reaction mixture of step 2 is then added to the final mixture of step 1.
  • the composition is continually mixed while cooling to 40° C.
  • step 3 of the method of manufacture according to this embodiment of the invention salicylic acid and water are premixed and added to the resultant composition of step 2.
  • step 4 of the method of manufacture according to this embodiment of the invention components water and sodium benzoate are premixed and added to the resultant composition of step 3.
  • step 5 of the method of manufacture according to this embodiment of the invention lauramide DEA (and) linoleamide DEA, and fragrance are added to the resultant composition of step 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

Topical personal care compositions comprising an anti-inflammatory agent, a surfactant, a bodifier/humectant, and water and methods of use are disclosed.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. patent application Ser. No. 11/054,883 filed on Feb. 10, 2005.
  • BACKGROUND OF THE INVENTION
  • Topical personal care compositions containing the anti-inflammatory agent cortisone are well known in the art. Adrenal corticosteroids, and the synthetic analogues thereof, are active pharmaceutical compounds with the known characteristic of preventing the development of, or suppressing existing, localized heat, redness, tenderness and swelling which characterizes any inflammation of skin or mucous membrane, regardless of the causal factor. The unique biochemical, pharmacologic and physiologic properties of corticosteroids make them extremely useful in the topical treatment of inflammatory conditions in subjects.
  • It is known that anti-inflammatory agents are effective in the treatment of various skin and scalp disorders such as psoriasis, seborrhea, dermatitis, dandruff, and the like. However, these compounds generally have been available in non-rinse vehicles which contain oils or emulsions which give the hair or skin a soiled appearance.
  • Surfactants may be added to an anti-inflammatory agent containing formulations to improve the appearance of hair and scalp. For example, U.S. Pat. No. 4,835,148, describes a shampoo composition comprising a water insoluble anti-inflammatory agent and an anionic surfactant. U.S. Pat. No. 5,665,364, describes a topical personal care composition comprising both an anionic surfactant and an amphoteric surfactant, and an active ingredient, one of which may be hydrocortisone. While the addition of an anionic surfactant has been shown to decrease the oily appearance of the hair, it is not considered to be a gentle cleanser and can overstrip the hair and dry the scalp. Therefore, there is a need to provide a topical personal care composition that combines an anti-inflammatory agent with an amphoteric surfactant, providing anti-dandruff and scalp treatment in a mild cleansing composition that is gentle on the hair and scalp, resulting in a more cosmetically desirable appearance.
  • SUMMARY OF THE INVENTION
  • One or more embodiments of the present invention relate to topical personal care compositions comprising an effective amount of an anti-inflammatory agent, an effective amount of an surfactant, an effective amount of a bodifier/humectant, and water.
  • Certain embodiments of the present invention pertain to providing a gentle cleanser with a decreased likelihood of irritancy, while still allowing for a level of lather production that is acceptable to the consumer. While embodiments of the invention should not be limited by a particular principle, it is believed that these characteristics may be achieved in the current composition through the use of a surfactant as the cleansing agent. Certain embodiments of the present invention provide topical personal care compositions which contain a mild cleanser and do not overstrip the hair and/or dry the skin.
  • Embodiments of the present invention also relate to increasing the diameter of the hair shaft as well as moderating damage to the hair caused by environmental or other factors. This result may be effectuated though the use of a bodifier/humectant that is sorbable onto or into the shafts of the hair and is able to remain with the hair for a reasonable period of time. Additionally, the bodifier/humectant is believed to decrease the friction between individual shafts of hair, thereby decreasing abrasion damage caused by brushing or combing. This embodiment of the present invention provides topical personal care compositions containing a cosmetically effective amount of a bodifier/humectant that can both increase the diameter of the hair shafts and moderate damage to the hair.
  • DETAILED DESCRIPTION
  • One or more embodiments of the invention pertain to topical personal care compositions which are applied to hair and/or skin. In one aspect of the invention the topical personal care composition is worked through wet hair, and later rinsed off to provide the consumer with a scalp treatment in a mild cleansing composition that is gentle on the hair and scalp. In some aspects of the present invention the topical personal care compositions are selected from the group consisting essentially of a body wash, cream, lotion, spray or shampoo.
  • According to one embodiment of the invention, the topical personal care composition comprises about 0.1% to about 5.0% of an anti-inflammatory agent; about 15.0% to about 55.0% of an amphoteric surfactant; about 0.1% to about 9.0% of bodifier/humectant; and water. In another embodiment of the invention, the anti-inflammatory agent in the above composition includes hydrocortisone. In yet another embodiment of the invention, the amphoteric surfactant in the above composition includes cocamidopropyl hydroxysultaine. In a further embodiment of the invention, the bodifier/humectant includes panthenol, panthenyl ethyl ether, or phytantriol, or mixtures thereof.
  • In still another embodiment, the anti-inflammatory agent includes hydrocortisone, the amphoteric surfactant includes cocamidopropyl hydroxysultaine, and the bodifier/humectant includes a mixture of panthenol, panthenyl ethyl ether, and phytantriol.
  • In a further embodiment of the invention, the composition comprises: about 0.1% to about 5.0% hydrocortisone; about 15.0% to about 55.0% cocamidopropyl hydroxysultaine; about 0.1% to about 9.0% panthenol, about 0.1% to about 9.0% panthenyl ethyl ether, and about 0.1% to about 9.0% phytantriol; and about 25.0% to about 70.0% water.
  • In still another embodiment of the invention, the composition is composed of: about 0.9% to about 1.1% hydrocortisone; about 30% to about 40% cocamidopropyl hydroxysultaine; about 1.0% to about 5.0% panthenol, about 0.5% to about 0.9% panthenyl ethyl ether, and about 0.1% to about 0.5% phytantriol; and about 25.0% to about 70.0% water.
  • Another aspect of the invention concerns a method of shampooing hair wherein an effective amount of an anti-inflammatory agent is deposited on the scalp comprising the steps of: (a) applying an effective amount of the topical personal care composition to hair that has been wetted; (b) working said composition through said hair; and (c) rinsing said composition from said hair.
  • According to one or more embodiments of this method aspect, the compositions comprise at least about 0.1% to about 6.0% of an anti-inflammatory agent. Preferably the amount is from about 0.5% to about 4.0%, more preferably from about 0.9% to about 3.1%.
  • Any type of known anti-inflammatory agent may be useful in compositions of the present invention. One preferred category of anti-inflammatory agents is the adrenal corticosteroids. A preferred anti-inflammatory agent is hydrocortisone, a known anti-inflammatory agent which exists and is commercially available. Another preferred anti-inflammatory agent is salicylic acid, a known anti-inflammatory agent which exists and is commercially available.
  • One component of the present compositions is a surfactant, which is for the delivery of conditioning agents to the hair and skin. In one aspect of the invention the A preferred amphoteric surfactant is and amphoteric surfactant. A preferred amphoteric surfactant is cocamidopropyl hydroxysultaine. Amphoterics (also known as surface-active agents) possess both a positive and a negative electrical charge and are capable of reacting as either an acid or an alkali, depending upon the rest of the formula. They are promoted to cosmetic manufacturers (and thus indirectly to consumers) as being milder and more desirable than the anionic surfactants.
  • According to one or more embodiments of this method aspect, the compositions comprise at least about 15.0% to about 55.0% of an amphoteric surfactant. Preferably the amount is from about 30.0% to about 40.0%.
  • Further examples of amphoteric surfactants which can be used in the compositions of embodiments of the present invention are those broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Examples of compounds falling within this definition are sodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminopropane sulfonate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isothionate according to the teaching of U.S. Pat. No. 2,658,072, N-higher alkyl aspartic acid esters such as those produced according to the teaching of U.S. Pat. No. 2,438,091, and the products sold under the trade name “Miranol” and described in U.S. Pat. No. 2,528,378.
  • Certain embodiments of the invention incorporate a bodifier/humectant that increases the diameter of the hair shafts and moderates the damage that environmental or other factors may have caused to hair or skin. The bodifier remains with the hair and skin for a reasonable length of time to minimize future damage. One preferred bodifier is comprised of panthenol, panthenyl ethyl ether, phytantriol, or mixtures thereof, and will comprise an effective amount of a bodifier/humectant, generally about 0.1% to about 9.0% by weight of the composition. The bodifier/humectant according to certain embodiments of the present invention is also effective in moisturizing the skin.
  • According to one or more embodiments of this method aspect, the compositions comprise at least about 0.1% to about 9.0% of a bodifier/humectant. Preferably the amount is from about 0.1% to about 5.0%.
  • Water is also an ingredient in the compositions according to embodiments of the present invention. According to one or more embodiments, the compositions contain from about 25.0% to about 70.0% water, preferably from about 34.0% to about 62.0%
  • Additional components of compositions may include, but are not limited to: preservatives, such as sodium benzoate, methylchloroisothiazolinone, and methylisothiazolinone; anti-fungal agents, such as methylparaben and propylparaben; PEG-6000 distearate; lauramide DEA and linoleamide DEA; glycol stearate; and fragrance.
  • In one or more embodiments of the invention, anti-dandruff agents are also present in the shampoo compositions. Included among such agents are coal tar, sulfur, selenium sulfide, salicyclic acid, pyridinethione metal salts (e.g., zinc), ether 1-hydroxy pyridones such as those described in U.S. Pat. No. 4,185,106, and azole antimycotics disclosed in British Pat. No. 1,502,144, both of which patents are incorporated herein by reference in their entirety. When present, this additional anti-dandruff agent comprises from about 0.1% to about 7.0% of the composition, preferably from about 0.2% to about 2.0%.
  • The topical personal care compositions according to certain embodiments of the present invention may also comprise a suspending agent. The suspending agent useful can be one of several agents, such as for example, ethylene glycol esters of fatty acids containing from about 16 to about 22 carbon atoms, preferably from about 16 to about 18 carbon atoms.
  • In embodiments that utilize ethylene glycol esters, which may include diesters wherein the esters are a mixture of palmitate and stearate. The amount of stearate should be in the range of about 5.0% to about 20.0% or in the range of about 95.0% to about 80.0% with palmitate accounting for the remainder. The amount of stearate is preferably from about 5.1% to about 10.5%. The distearates found to be useful in certain embodiments of the compositions of the present invention range from about 5.0% to about 10.0%.
  • According to certain embodiments, alkanol amides of fatty acids containing from about 16 to about 22 carbon atoms, preferably from about 16 to about 18 carbon atoms may be useful. Preferred alkanol amides are stearic monoethanolamide stearic diethanolamide, stearic monoisopropanolamide and stearic monoethanolamide stearate. Another useful group of suspending agents are alkyl dimethylamine oxides, wherein the alkyl group contains from about 16 to about 22 carbon atoms such as stearyldimethyl amine oxide.
  • Mixtures of the above suspending agents may also be used. Compositions according to certain embodiments of the invention comprise from about 2.0% to about 11.0% of the suspending agent, preferably from about 5.0% to about 7.0%.
  • The topical personal care compositions according to one or more embodiments of the present invention can contain a variety of other nonessential optional components suitable for rendering such compositions more acceptable. Such conventional optional ingredients are well known to those skilled in the art, e.g., preservatives such as benzyl alcohol, methyl paraben, propyl paraben, methylisothiazolinone and imidazolidinyl urea; thickeners and viscosity modifiers such as amine oxides, block polymers of ethylene oxide and propylene oxide such as Pluronic F88 offered by BASF Wyandotte, fatty alcohols such as cetearyl alcohol, sodium chloride, ammonium chloride, sodium sulfate, polyvinyl alcohol, propylene glycol and ethyl alcohol; hydrotopes such as xylene sulfonate, amine sulfonate, and polyethylene glycol; pH adjusting agents such as citric acid, succinic acid, phosphoric acid, sodium hydroxide, sodium carbonate, etc.; perfumes; dyes; quaternary ammonium compounds such as Polyquaternium 41; and, sequestering agents such as disodium ethylenediamine tetraacetate. Such agents generally are used individually at a level of from about 0.01% to about 10.0%, preferably from about 0.01% to about 5.0% by weight of the composition.
  • In certain preferred embodiments, the compositions are free of clays and polymeric thickeners. The term “free” as used herein refers to less than about 20 ppm.
  • The following Examples further describe and demonstrate the preferred embodiments within the scope of the present invention. The Examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention as many variations thereof are possible without departing from its spirit and scope.
  • EXAMPLES Example I
  • The following composition is representative of the present invention.
  • Component Weight %
    Hydrocortisone 1.0%
    Panthenol 1.0-5%  
    Phytantriol 0.1-0.5%
    Panthenyl Ethyl Ether 0.5-0.9%
    Cocamidopropyl Hydroxysultaine 30.0%-40.0% 
    Water qs
  • Example II
  • The following composition is also representative of the present invention and is prepared as follows:
  • Component Weight %
     1. Hydrocortisone  1.0%
     2. Water QS
     3. Cocamidopropyl Hydroxysultaine 30.0%-40.0%
     4. PEG-6000 Distearate  5.0%-10.0%
     5. Panthenol 1.0%-5.0%
     6. Lauramide DEA 1.0%-5.0%
     7. Panthenyl Ethyl Ether 0.5%-0.9%
     8. Lauramide DEA (and) Linoleamide DEA 0.5%-0.9%
     9. Glycol Stearate 0.1%-0.5%
    10. Fragrance 0.1%-0.5%
    11. Phytantriol 0.1%-0.5%
    12. Methylparaben 0.1%-0.3%
    13. Propylparaben 0.1%-0.3%
    14. Sodium Benzoate 0.1%-0.3%
    15. Methylchloroisothiazolinone <0.1%
    16. Methylisothiazolinone <0.1%
  • The composition of Example II is prepared according to the following procedure:
  • In step 1 of this method of manufacture water is heated to 75° C. and panthenol, lauramide DEA, panthenyl ethyl ether, phytantriol, and methylchloroisothiazolinone are added. The reaction components of step 1 are mixed and the temperature is maintained at 75° C.
  • In step 2 of the method of manufacture according to this embodiment of the invention, components cocamidopropyl hydroxysultaine, PEG-6000 distearate, glycol stearate, methylparaben, and propylparaben are mixed and heated to 75° C. until the components are dissolved. The resultant reaction mixture of step 2 is then added to the final mixture of step 1. The composition is continually mixed while cooling to 40° C.
  • In step 3 of the method of manufacture according to this embodiment of the invention, hydrocortisone and water are premixed and added to the resultant composition of step 2.
  • In step 4 of the method of manufacture according to this embodiment of the invention, components water and sodium benzoate are premixed and added to the resultant composition of step 3.
  • In step 5 of the method of manufacture according to this embodiment of the invention, lauramide DEA (and) linoleamide DEA, and fragrance are added to the resultant composition of step 4.
  • Example III
  • The following composition is also representative of the present invention.
  • Component Weight %
    Salicylic acid 3.0%
    Panthenol 1.0-5%  
    Phytantriol 0.1-0.5%
    Panthenyl Ethyl Ether 0.5-0.9%
    Cocamidopropyl Hydroxysultaine 30.0%-40.0% 
    Water qs
  • Example IV
  • The following composition is also representative of the present invention and is prepared as follows:
  • Component Weight %
     1. Salicylic acid  3.0%
     2. Water QS
     3. Cocamidopropyl Hydroxysultaine 30.0%-40.0%
     4. PEG-6000 Distearate  5.0%-10.0%
     5. Panthenol 1.0%-5.0%
     6. Lauramide DEA 1.0%-5.0%
     7. Panthenyl Ethyl Ether 0.5%-0.9%
     8. Lauramide DEA (and) Linoleamide DEA 0.5%-0.9%
     9. Glycol Stearate 0.1%-0.5%
    10. Fragrance 0.1%-0.5%
    11. Phytantriol 0.1%-0.5%
    12. Methylparaben 0.1%-0.3%
    13. Propylparaben 0.1%-0.3%
    14. Sodium Benzoate 0.1%-0.3%
    15. Methylchloroisothiazolinone <0.1%
    16. Methylisothiazolinone <0.1%
  • The composition of Example IV is prepared according to the following procedure:
  • In step 1 of this method of manufacture water is heated to 75° C. and panthenol, lauramide DEA, panthenyl ethyl ether, phytantriol, and methylchloroisothiazolinone are added. The reaction components of step 1 are mixed and the temperature is maintained at 75° C.
  • In step 2 of the method of manufacture according to this embodiment of the invention, components cocamidopropyl hydroxysultaine, PEG-6000 distearate, glycol stearate, methylparaben, and propylparaben are mixed and heated to 75° C. until the components are dissolved. The resultant reaction mixture of step 2 is then added to the final mixture of step 1. The composition is continually mixed while cooling to 40° C.
  • In step 3 of the method of manufacture according to this embodiment of the invention, salicylic acid and water are premixed and added to the resultant composition of step 2.
  • In step 4 of the method of manufacture according to this embodiment of the invention, components water and sodium benzoate are premixed and added to the resultant composition of step 3.
  • In step 5 of the method of manufacture according to this embodiment of the invention, lauramide DEA (and) linoleamide DEA, and fragrance are added to the resultant composition of step 4.
  • Even though the invention herein has been described with reference to particular examples and embodiments, it is to be understood that these examples and embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the following claims.

Claims (19)

1. A hair composition comprising:
(a) an effective amount of a hydrocortisone;
(b) an effective amount of a surfactant;
(c) an effective amount of bodifier/humectant; and
(d) water.
2. The composition of claim 1, wherein the mixture comprises about 1.0% to about 5.0% of hydrocortisone.
3. The composition of claim 1, wherein the mixture comprises about 1.0% of hydrocortisone.
4. The composition of claim 1, wherein the mixture comprises about 2.0% of hydrocortisone.
5. The composition of claim 1, wherein the mixture comprises about 3.0% of hydrocortisone.
6. The composition of claim 1, wherein the mixture comprises about 4.0% of hydrocortisone.
7. The composition of claim 1, wherein the mixture comprises about 5.0% of hydrocortisone.
8. The composition of claim 1, wherein the surfactant is cocamidopropyl hydroxysultaine.
9. The composition of claim 1, wherein the bodifier/humectant is selected from the group consisting of panthenol, panthenyl ethyl ester, or phytantriol, or mixtures thereof.
10. The composition of claim 1, wherein the anti-inflammatory agent is hydrocortisone, the amphoteric surfactant is cocamidopropyl hydroxysultaine, and the bodifier/humectant is a mixture of panthenol, panthenyl ethyl ether, and phytantriol.
11. The composition of claim 10, wherein the mixture comprises about 0.1% to about 5.0% hydrocortisone; about 15.0% to about 55.0% cocamidopropyl hydroxysultaine; about 0.1% to about 9.0% panthenol, about 0.1% to about 9.0% panthenyl ethyl ether, and about 0.1% to about 9.0% phytantriol; and about 25.0% to about 70.0% water.
12. The composition of claim 10, wherein the mixture comprises about 1.0% hydrocortisone; about 30% to about 40% cocamidopropyl hydroxysultaine; about 1.0% to about 5.0% panthenol, about 0.5% to about 0.9% panthenyl ethyl ether, and about 0.1% to about 0.5% phytantriol; and about 25.0% to about 70.0% water.
13. The composition according to claim 1, wherein the composition is in a product selected from the group consisting essentially of a shampoo, body wash, cream, spray or lotion.
14. A method of shampooing hair wherein an effective amount of an anti-inflammatory agent is deposited on the scalp comprising the steps of:
(a) applying said composition according to claim 11 to hair that has been wetted;
(b) working said composition through said hair; and
(c) rinsing said composition from said hair.
15. A method of shampooing hair wherein an effective amount of an anti-inflammatory agent is deposited on the scalp comprising the steps of:
(a) applying said composition according to claim 12 to hair that has been wetted;
(b) working said composition through said hair; and
(c) rinsing said composition from said hair.
16. A method of shampooing hair wherein an effective amount of an anti-inflammatory agent is deposited on the scalp comprising the steps of:
(a) applying said composition according to claim 11 to hair that has been wetted;
(b) working said composition through said hair;
(c) rinsing said composition from said hair;
(d) applying a second composition to said hair, comprising about 3.0% to about 6.0% salicylic acid; about 15.0% to about 55.0% cocamidopropyl hydroxysultaine; about 0.1% to about 9.0% panthenol, about 0.1% to about 9.0% panthenyl ethyl ether, and about 0.1% to about 9.0% phytantriol; and about 25.0% to about 70.0% water;
(e) working said composition through said hair; and
(f) rinsing said composition from said hair.
17. A topical personal care composition comprising, panthenol, phytantriol, panthenyl ethyl ether, cocamidopropyl hydroxysultaine, water, PEG-6000 distearate, lauramide DEA, linoleamide DEA, glycol stearate, fragrance, methylchloroisothiazolinone, methylisothiazolinone, methylparaben, propylparaben, and sodium benzoate.
18. A topical personal care composition according to claim 17, comprising about 0.1% to about 5.0% hydrocortisone hydrocortisone, 0.1% to about 9.0% panthenol, about 0.1% to about 9.0% panthenyl ethyl ether, and about 0.1% to about 9.0% phytantriol, 30% to about 40% cocamidopropyl hydroxysultaine, about 25.0% to about 70.0% water, about 5.0% to about 10% PEG-6000 distearate, about 0.5% to about 0.9% lauramide DEA, about 0.5% to about 0.9% linoleamide DEA, about 0.1% to about 0.5% glycol stearate, about 0.1% to about 0.5% fragrance, less than about 0.1% methylchloroisothiazolinone, less than about 0.1% methylisothiazolinone, about 0.1% to about 0.3% methylparaben, about 0.1% to about 0.3% propylparaben, and about 0.1% to about 0.3% sodium benzoate.
19. The method according to claim 16 wherein the second composition comprises about 3.0% to about 6.0% salicylic acid, 0.1% to about 9.0% panthenol, about 0.1% to about 9.0% panthenyl ethyl ether, and about 0.1% to about 9.0% phytantriol, 30% to about 40% cocamidopropyl hydroxysultaine, about 25.0% to about 70.0% water, about 5.0% to about 10% PEG-6000 distearate, about 0.5% to about 0.9% lauramide DEA, about 0.5% to about 0.9% linoleamide DEA, about 0.1% to about 0.5% glycol stearate, about 0.1% to about 0.5% fragrance, less than about 0.1% methylchloroisothiazolinone, less than about 0.1% methylisothiazolinone, about 0.1% to about 0.3% methylparaben, about 0.1% to about 0.3% propylparaben, and about 0.1% to about 0.3% sodium benzoate.
US12/492,681 2005-02-10 2009-06-26 Topical Personal Care Compositions And Methods of Use Abandoned US20090264390A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/492,681 US20090264390A1 (en) 2005-02-10 2009-06-26 Topical Personal Care Compositions And Methods of Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/054,883 US7553480B2 (en) 2005-02-10 2005-02-10 Topical personal care compositions and methods of use
US12/492,681 US20090264390A1 (en) 2005-02-10 2009-06-26 Topical Personal Care Compositions And Methods of Use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/054,883 Continuation US7553480B2 (en) 2005-02-10 2005-02-10 Topical personal care compositions and methods of use

Publications (1)

Publication Number Publication Date
US20090264390A1 true US20090264390A1 (en) 2009-10-22

Family

ID=36780217

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/054,883 Expired - Fee Related US7553480B2 (en) 2005-02-10 2005-02-10 Topical personal care compositions and methods of use
US12/492,681 Abandoned US20090264390A1 (en) 2005-02-10 2009-06-26 Topical Personal Care Compositions And Methods of Use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/054,883 Expired - Fee Related US7553480B2 (en) 2005-02-10 2005-02-10 Topical personal care compositions and methods of use

Country Status (1)

Country Link
US (2) US7553480B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553480B2 (en) * 2005-02-10 2009-06-30 Pure USA, LLC Topical personal care compositions and methods of use
US8933134B2 (en) 2010-06-09 2015-01-13 L'oreal Compositions containing agar and a softening agent

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438091A (en) * 1943-09-06 1948-03-16 American Cyanamid Co Aspartic acid esters and their preparation
US2528378A (en) * 1947-09-20 1950-10-31 John J Mccabe Jr Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same
US2658072A (en) * 1951-05-17 1953-11-03 Monsanto Chemicals Process of preparing amine sulfonates and products obtained thereof
US4185106A (en) * 1972-07-11 1980-01-22 Hoechst Aktiengesellschaft Pyridones as antidandruff agents
US4472421A (en) * 1974-06-22 1984-09-18 Bayer Aktiengesellschaft Azole antimycotics and their use in treating skin conditions caused by Pityrosporum ovale
US4656043A (en) * 1985-09-13 1987-04-07 Richardson-Vicks Inc. Peroxide-containing conditioning shampoo
US4722837A (en) * 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
US4835148A (en) * 1986-02-24 1989-05-30 The Procter & Gamble Co. Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents
US5665364A (en) * 1995-07-24 1997-09-09 The Procter & Gamble Company Compositions for topical delivery of active ingredients
US7553480B2 (en) * 2005-02-10 2009-06-30 Pure USA, LLC Topical personal care compositions and methods of use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438091A (en) * 1943-09-06 1948-03-16 American Cyanamid Co Aspartic acid esters and their preparation
US2528378A (en) * 1947-09-20 1950-10-31 John J Mccabe Jr Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same
US2658072A (en) * 1951-05-17 1953-11-03 Monsanto Chemicals Process of preparing amine sulfonates and products obtained thereof
US4185106A (en) * 1972-07-11 1980-01-22 Hoechst Aktiengesellschaft Pyridones as antidandruff agents
US4472421A (en) * 1974-06-22 1984-09-18 Bayer Aktiengesellschaft Azole antimycotics and their use in treating skin conditions caused by Pityrosporum ovale
US4722837A (en) * 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
US4656043A (en) * 1985-09-13 1987-04-07 Richardson-Vicks Inc. Peroxide-containing conditioning shampoo
US4835148A (en) * 1986-02-24 1989-05-30 The Procter & Gamble Co. Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents
US5665364A (en) * 1995-07-24 1997-09-09 The Procter & Gamble Company Compositions for topical delivery of active ingredients
US7553480B2 (en) * 2005-02-10 2009-06-30 Pure USA, LLC Topical personal care compositions and methods of use

Also Published As

Publication number Publication date
US20060177471A1 (en) 2006-08-10
US7553480B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
US5834409A (en) Scalp care products containing anti itching/anti irritant agents
US6624126B1 (en) Personal cleansing composition comprising a glyceryl ether
US6566313B1 (en) Shampoo and body wash composition and method of use thereof
AU659520B2 (en) Stable conditioning shampoo containing fatty acid
US5576279A (en) Stable conditioning shampoo containing an anionic surfactant a fatty alcohol, and polyethyleneimine
AU631721B2 (en) Topical composition
EP0562639B1 (en) Shampoo compositions and suspending agent therefor
US20030228272A1 (en) Novel antidandruff conditioning shampoo
US6113892A (en) Compositions for cleansing, conditioning and moisturizing hair and skin
AU678450B2 (en) Stable conditioning shampoo containing an anionic surfactant, a fatty alcohol, a silicone conditioner and polyethyleneimine
US5078991A (en) Topical composition
RU2004122432A (en) SUSTAINABLE SURFACE-ACTIVE COMPOSITIONS FOR SUSPENDING COMPONENTS
US5900393A (en) Scalp care products containing anti itching /anti irritant agents
CN107822970A (en) A kind of anti-dandruff Essence and preparation method thereof
US5686403A (en) Cleanser composition containing phosphate ester and ether acetate surfactants
US7553480B2 (en) Topical personal care compositions and methods of use
AU628022B2 (en) Shampoo composition
JP2676155B2 (en) Hair restoration
AU8270798A (en) Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof
GB2220216A (en) Washing and conditioning hair
US20030077239A1 (en) Composition for the antidandruff treatment of the hair and scalp based on an antidandruff active principle and on a hydroxy acid
US3697655A (en) Germicidal detergent compositions in controlling dandruff
US3123531A (en) Shampoo composition comprising beta-di-
KR100983207B1 (en) Cosmetic composition
WO1994018934A1 (en) Hair care compositions containing a silicone compound and a quaternary ammonium compound

Legal Events

Date Code Title Description
AS Assignment

Owner name: PURE USA, LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WAGH, ASHER;REEL/FRAME:022890/0805

Effective date: 20050727

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION